New antibiotic class showing no resistance development

GmPcides are a new class of antibiotics effective against multidrug resistant gram-positive bacteria such as Staphylococcus aureus, Streptococcus pyogenes and Enterococcus ssp, including drug-resistant strains such as MRSA and VRE. GmPcides belong to a new chemical class, have new target and a new mode of action and there is no cross-resistance to other antibiotic class, i.e. they fulfil all four WHO innovativeness criteria.

QureTech Bio’s lead program is focusing on developing a new monotherapy for treatment of serious infections caused by Gram-positive bacteria. The program is supported by ENABLE-2 (financed by Vinnova) and is currently in lead optimization phase.

New class

Novel family of small molecules with excellent microbiological profile based on a robust and reliable chemical platform that allows fine tuning of properties important for drug development.

Bactericidal effect on antibiotic-resistant bacteria

GmPcides effectively kills bacteria, including MRSA in biofilm and MRSA persisters.

No pre-existing resistance

MIC90 in recent clinical isolates of S. aureus and Enterococcus ssp show a narrow distribution of MICs and there are no signs of pre-existing reduced susceptibility to GmPcides.

Novel mechanism of action

GmPcides target regulatory proteins controlling metabolism and virulence, and to our knowledge, these regulatory proteins have not been targeted before.

Key Publications

  • Chemical disarming of isoniazid resistance in Mycobacterium tuberculosis
    Flentie K, Harrison GA, Tükenmez H, Livny J, Good JAD, Sarkar S, Zhu DX, Kinsella RL, Weiss LA, Solomon SD, Schene ME, Hansen MR, Cairns AG, Kulén M, Wixe T, Lindgren AEG, Chorell E, Bengtsson C, Krishnan KS, Hultgren SJ, Larsson C, Almqvist F, Stallings CL. Proc Natl Acad Sci U S A. 2019 May 21;116(21):10510-10517.

    doi: 10.1073/pnas.1818009116.